Graft-versus-host disease (GVHD)

Graft-versus-host disease (GVHD) is a systemic immune-mediated complication of allogeneic (donor) hematopoietic stem cell or bone marrow transplantation, in which donor immune cells (primarily T lymphocytes) attack the recipient's tissues, recognizing them as foreign. GVHD can be acute or chronic, with acute forms typically affecting skin, liver, and gastrointestinal tract, while chronic forms can involve almost any organ. GVHD is managed with various immunosuppressive therapies, and steroid-refractory GVHD is a significant therapeutic challenge[1][2][3][5][7][10]. In summary, "Graft-versus-host disease" is not a molecular or protein target, but a complex immunologic disorder and major complication of transplantation. This entry is thus considered incorrect as a drug target per standard categorization.

Other names

GvHDGVHDGraft versus host diseaseGraft-vs-host disease

Immunosuppression (corticosteroids, calcineurin inhibitors, mycophenolate mofetil, sirolimus, azathioprine, antithymocyte globulin) Targeted inhibition of signaling pathways (ibrutinib – BTK inhibitor) Cell therapies modulating immune cell response (decidua or mesenchymal stromal cells)[1][2][4]